Search Results

Allecra Therapeutics and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024.

SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America.

Acino today announced that it has completed the acquisition of M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

Acino announced that it has entered into an agreement to acquire M8 Pharmaceuticals, a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.